IGF1 and retinopathy of prematurity: The possibility that supplemental IGF-1 given from 24 h of birth until reaching 30 weeks postmenstrual age (PMA) might prevent severe ROP was tested in a clinical trial with intravenous infusions of supplemental recombinant human IGF-1 combined with recombinant human IGF-1 binding protein.